Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms
Keywords
Abstract
Description
Multiple studies have subsequently used higher dose of prednisolone in infantile spasms at the weight based dosing of 4-8 mg/kg/day with a maximum dose of 60mg/day. The results have shown high rates of clinical and elecroencephalographic remission with lower relapse rates.However, a major concern related to corticosteroids, especially in infants and children, is the possible development of side effects. The most frequent ones are excessive weight gain, hyperphagia, water retention with edema, cushingoid appearance, hypertension, behavioral disturbances, increased infection susceptibility, leukopenia, electrolyte disturbances, hyperglycemia, glycosuria, impaired glucose tolerance, frank diabetes and sleep disorders. Furthermore, long-term side effects such as hypothalamus-pituitary axis suppression, psychosis, osteoporosis, nephrocalcinosis, brain atrophy, cataracts and, in children, growth retardation, have also been reported.
Recently, role of intravenous methylprednislone pulse therapy has been explored as one of the therapeutic modality in IS, in order to avoid the development of side-effects associated with prolonged oral steroid therapy and maintain long-term efficacy. There have been few studies on use of iv pulse methylprednisolone in IS with small sample size, showing to a rapid improvement in EEG & cessation of spasm in majority of the infants without significant adverse effects.
Emerging evidence suggests that intravenous pulse methylprednisolone might have superior efficacy and better safety profile when compared to high dose oral prednisolone in treatment of IS.
Hence, present study aims at comparing intravenous pulse methylprednisolone versus oral prednisolone in an open label, RCT for treatment of children with IS.
Dates
| Last Verified: | 10/31/2019 |
| First Submitted: | 03/11/2019 |
| Estimated Enrollment Submitted: | 03/12/2019 |
| First Posted: | 03/14/2019 |
| Last Update Submitted: | 11/13/2019 |
| Last Update Posted: | 11/17/2019 |
| Actual Study Start Date: | 03/31/2019 |
| Estimated Primary Completion Date: | 04/29/2022 |
| Estimated Study Completion Date: | 10/30/2022 |
Condition or disease
Intervention/treatment
Drug: Intervention arm
Drug: Control
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Intervention arm Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day | Drug: Intervention arm Intravenous Methylprednisolone will be used in the intervention group |
| Active Comparator: Control Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day | Drug: Control Oral Prednisolone will be used in the Control Group |
Eligibility Criteria
| Ages Eligible for Study | 4 Months To 4 Months |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: Newly diagnosed patients aged 4 - 30 months with epileptic spasms in clusters with electroencephalographic evidence of hypsarrhythmia or its variants with or without developmental delay - Exclusion Criteria: 1. Children with recognized progressive neurological illness will be excluded. 2. Children with chronic renal, pulmonary, cardiac or hepatic dysfunction 3. Severe malnutrition (weight for length and height for less than 3 SD for mean as per WHO growth charts) - |
Outcome
Primary Outcome Measures
1. Proportion of children who achieved spasm freedom as per parental reports in both the groups [6 weeks]
Secondary Outcome Measures
1. Number of days after initiation of trial treatment on which spasms were not seen and after which response was maintained until 6 weeks (day 42) of treatment in both the groups [6 weeks]
2. Proportion of children who achieve resolution of hypsarrhythmia on electro encephalogram at 2 weeks (in all cases) and at 6 weeks (for cases with sustained clinical response) in both the groups. [6 weeks]
3. Description and proportion of the adverse effects of methylprednisolone in the experimental group [6 weeks]
